212P - D2 lymphadenectomy with preservation of the spleen in gastric cancer

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Gastric Cancer
Surgical Oncology
Radiation Oncology
Presenter Evgeny Glukhov
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors E. Glukhov1, I. Stilidi2, S. Nered1
  • 1Abdominal Oncology, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2Abdominal Oncology, N. N. Blokhin Russian Cancer Research Center, 115438 - Moscow/RU



To determine the relevance of splenectomy in patients with gastric cancer.


From 2005 to 2014, 352 patients suffering from cancer of middle and upper third gastric cancer underwent radical D2 gastrectomy. 197 cases had D2 gastrectomy with splenectomy (group A), 155 patients underwent spleen preservation D2 gastrectomy (group B). Method includes standard D2 lymphadenectomy and en bloc removal of tissue and lymph nodes (10 group) in the gate of the spleen.


Average number of removed lymph nodes and 10 groups (JGCA) between the two groups did not differ and were 29,3/33,8 and 2,3/2,6, respectively. Morbidity and mortality in group A were 36,5% and 1,5%, in group B-20% and 0%. 5-year survival in groups A and B were 55% and 59% (р > 0,05), respectively.


D2 gastrectomy with preservation of the spleen is a radical method of surgical treatment patients with gastric cancer. Splenectomy is an element of lymphadenectomy D2, which leads to an increased risk of postoperative complications in patients with gastric cancer.

Clinical trial identification

non-randomized single-centre prospective study


All authors have declared no conflicts of interest.